EC Approves Gilead's Viread for HIV-1 Infection in Children, Adolescents

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the EuropeanCommission has granted marketing authorization for two new indications foronce-daily Viread^® (tenofovir disoproxil fumarate). The first new indicationpermits the use of Viread in combination with other antiretroviral agents forthe treatment of HIV-1 infected pediatric patients aged 2 to less than 18years with nucleoside reverse transcriptase inhibitor (NRTI) resistance ortoxicities precluding the use of first line pediatric agents. Additionally,Viread is now approved for the treatment of chronic hepatitis B virus (HBV)infection in adolescent patients aged 12 to less than 18 years withcompensated liver disease and evidence of immune active disease. Today'sauthorization covers all 27 countries of the European Union (EU). Viread wasapproved for use in combination with other antiretroviral agents as atreatment for HIV-1 infection in adults and for chronic HBV in 2002 and 2008,respectively, and is the most-prescribed molecule for these diseases in majorEuropean countries.